Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Theriva Biologics, Inc. Common Stock (NY: TOVX )

1.760 +0.460 (+35.38%)
Official Closing Price Updated: 5:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Theriva Biologics, Inc. Common Stock

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
US Stocks To Open Higher On Shortened Trading Day: Santa Claus Rally Period Officially Begins, Says Analyst
U.S. stock futures advanced on Tuesday, head of a shortened trading session owning to Christmas-eve. The stock market will shut at 1 p.m. ET. 
Via Benzinga
Why Carbon Revolution Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
How Is The Market Feeling About Theriva Biologics?
Via Benzinga
Peering Into Theriva Biologics's Recent Short Interest
Via Benzinga
What's Going On With Theriva Biologics Stock Friday?
Theriva stock is trading higher after the company announced it was selected as a finalist for Merck's KGaA's EMEA Advance Biotech Grant. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Nasdaq Moves Lower; Levi Strauss Shares Slide
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Jumps Over 4%; US Services PMI Revised Lower
Via Benzinga
Exposures Fossil Fuels
Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients
Theriva Biologics announces DSMC approval to proceed to Cohort 3 in its SYN-004 trial for aGVHD prevention. No adverse events linked to SYN-004 were reported, supporting its continued development. 
Via Benzinga
Dow Dips Over 100 Points; US Jobless Claims Increase To 225,000
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
What's Going On With Theriva Biologics Stock?
Theriva Biologics shares are trading higher Friday on continued momentum following a series of catalysts this week. Here's a look at the details: 
Via Benzinga
Nasdaq Jumps Over 100 Points; Dell Posts Upbeat Results
Via Benzinga
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Theriva Biologics Receives Rare Pediatric Drug Designation From FDA For Treatment Of Retinoblastoma
Theriva Biologics Receives Rare Pediatric Drug Designation From FDA For Treatment Of Retinoblastoma 
Via News Direct
Exposures Product Safety
Nasdaq Surges 150 Points; Sonder Holdings Shares Surge
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.